Journal Reviews

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

1 March 2015 | | Urologic Oncology | Animal, BCG Connaught, BCG Tice, BCG vaccine, Flow cytometry, Immunotherapy, Intravesical drug administration, Models, Randomized controlled trial, Urinary bladder neoplasms

Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...